A clinical formulation indicated for HIV. Therapy acts to inhibit viral replication within the blood, which supports long-term viral suppression and optimizes immune system function.
A fixed-dose combination formulated to manage HIV-1 infection and designed to alleviate viral replication to support immune system health.
Mechanism of Action
Dolutegravir blocks the integrase enzyme. Lamivudine and Tenofovir block reverse transcriptase. Combined, they stop the HIV virus from integrating and multiplying in cells.
Route of Administration
Oral
Onset Time
Weeks for viral suppression
Duration
24 hours
Contraindications
Concurrent use of dofetilide, Hypersensitivity to any component
Severe Adverse Events
Lactic acidosis, Severe liver problems, Worsening of Hepatitis B, Immune reconstitution syndrome
Information for Viropil is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
